Presentations

Opthea to Present at the Jefferies 2023 Healthcare Conference

Dr. Megan Baldwin, the Company’s Chief Executive Officer will present at the Jefferies Healthcare Conference on June 7-9, 2023.

Webcast Registration Download PDF

EF Hutton Presentation May 2023

OPT-302 for wet AMD: VEGF C/D ‘trap’ to improve wet AMD vision outcomes

Download PDF Watch Recording

Opthea to Present at SVB Securities Global Biopharma Conference 2023

Opthea will present at SVB Securities Global Biopharma Conference on February 2, 2023, at 10:00 AM EST.

Webcast Registration Download PDF

Twilight Investor Briefing Featuring Megan Baldwin, CEO and MD Opthea Limited

Hosted by Monsoon Communications

February 7, 2023, 4:15pm

FB Rice: Level 33, 477 Collins St Melbourne VIC 3000

RSVP

Opthea Disclosure Confirmation Receipt

Opthea To Present at Sequire Biotechnology Conference Disclosure Confirmation Receipt

Download PDF

Corporate Presentation January 2023

Leading Therapeutic Innovation in Retinal Diseases

Download PDF

To view the MST Acess Hosted Conference Call, use the link below

Conference Call

This Presentation has been sourced from Opthea Limited (ABN 32 006 340 567) (“Information Provider”). MST Financial Services Pty Ltd (ACN. 617 475 180, AFSL 500557) (“MST”, “we”, “us”), holder of an Australian Financial Services Licence, its related bodies corporate and their respective officers, directors, employees, advisers, partners, affiliates and agents, make no representation or warranty, express or implied, as to the accuracy, completeness, timeliness or reliability of the contents of this presentation (including without limitation, liability for negligence). Statements in this presentation are made only as of the date of this presentation, unless otherwise stated, and the information in this Presentation remains subject to change without notice. Further we do not accept any responsibility to inform you of any matter that subsequently comes to our notice, that may affect the information disseminated in this presentation. To the fullest extent allowed by law, MST shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained in this report. Nothing contained in the Presentation is, or may be relied upon as, a promise, representation or warranty, whether as to the past or the future. No responsibility is accepted to update any person regarding any inaccuracy, omission or change in information in this Presentation or any other information made available to a person or any obligation to furnish the person with any further information. MST Financial (“MST”) materials, or any portion thereof, may not be reproduced, sold or redistributed without the prior and written consent of MST. MST Access reports, updates, video interviews and other materials produced by MST Access have generally been commissioned by the subject company. Please refer to full disclosures and disclaimers in the company-specific reports. MST discloses that within the past 12 months, MST and its associates have provided and received compensation for investment banking services, including acting as a Joint Lead Manager for the August 2022 capital raising of approximately U$90 million for Opthea Limited. MST also receives a fee from Opthea Limited for ongoing research coverage.

New approach in wet-AMD treatment: Efficacy and safety of dual inhibition of VEGF-C/-D and VEGF-A with OPT-302 combination therapy

Dr. Caroline Baumal, MD from the Tufts University School of Medicine, New England Eye Center, Boston, Massachusetts presented on OPT-302 combination therapy in wet AMD at the annual FLORetina congress.

Download PDF